ReviewInternational journal of nanomedicine2024
Research Progress on Chitosan Microneedle Arrays in Transdermal Drug Delivery.
Review in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Harnessing chitosan-based biomaterials for advanced cancer immunotherapy: from nanocarriers to tumor microenvironment modulation.Journal of nanobiotechnology · 2026Review
- Sustained-Release Microneedles for Local Delivery of Antibacterial Peptide in Acne Therapy.Polymers · 2026Article
- Recent Applications of Chitosan-Based Biomaterials as Wound Dressings.International journal of molecular sciences · 2026Review
- The multifaceted mechanisms of Tanshinone IIA in doxorubicin-induced cardiotoxicity.Frontiers in medicine · 2026Review
- Recent Advances in Novel Drug Delivery Systems for the Management of Cutaneous Squamous Cell Carcinoma.International journal of nanomedicine · 2026Review
- Article
- Hyaluronic Acid-Modified Celecoxib-Loaded Nanostructured Lipid Carriers Combined with Dissolving Microneedles for Targeted Sustained-Release Therapy in Osteoarthritis.International journal of nanomedicine · 2026Article
- Multi-Technology Empowers Dissolving Microneedles: A Novel Strategy in Rheumatoid Arthritis.Drug design, development and therapy · 2026Review
- Extracellular vesicles in chronic wound therapy: engineering strategies and advanced delivery systems for enhanced regeneration.Materials today. Bio · 2025Review
- Dissolvable Microneedles with Their Design, Materials, and Limitations in Translation: a Technical Review.AAPS PharmSciTech · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a type of transdermal drug delivery system (TDDS), Microneedles (MNs) have garnered significant attention from researchers due to their ability to penetrate the stratum corneum (SC) of the skin, enhance drug permeability and bioavailability, avoid first-pass metabolism, and cause minimal damage to the skin. This makes them particularly suitable for localized transdermal drug delivery. Dissolvable microneedles (DMNs) can encapsulate sensitive particles, provide high drug-loading capacity, and possess biodegradability and biocompatibility, attracting extensive research interest. Chitosan (CS) has been selected as the matrix for manufacturing DMNs due to its excellent properties, including not eliciting an immune response in vivo and having active functional groups such as hydroxyl and amino groups that allow for modifications to impart appropriate mechanical strength and functionality to DMNs for specific applications. This paper provides a comprehensive review of the research status of various chitosan-based microneedles (CSMNs), explores the mechanisms of their dissolution in vivo, and discusses their applications in promoting wound healing, delivering macromolecular drugs, vaccine delivery, and anti-tumor therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.